Jacques Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2053387/publications.pdf

Version: 2024-02-01

226 papers	15,110 citations	13332 70 h-index	25230 113 g-index
238 all docs	238 docs citations	238 times ranked	11455 citing authors

#	Article	IF	Citations
1	Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis: Five Years of Experience in a Clinical Laboratory. Clinical Chemistry, 2022, 68, 313-321.	1.5	7
2	Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. Reproductive BioMedicine Online, 2022, 44, 304-309.	1.1	5
3	Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. European Journal of Endocrinology, 2022, 186, 173-181.	1.9	10
4	Efficacy and tolerance of osilodrostat in patients with Cushingâ€™s syndrome due to adrenocortical carcinomas. European Journal of Endocrinology, 2022, 186, K1-K4.	1.9	11
5	Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2812-e2824.	1.8	6
6	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	0.6	23
7	Androgens and spermatogenesis. Annales D'Endocrinologie, 2022, 83, 155-158.	0.6	19
8	Congenital Hypogonadotropic Hypogonadism with Anosmia and Gorlin Features Caused by a PTCH1 Mutation Reveals a New Candidate Gene for Kallmann Syndrome. Neuroendocrinology, 2021, 111, 99-114.	1.2	20
9	Does Genetic Susceptibility of the Gonadotropic Axis Explain the Variable Impact of Stressors Causing Functional Hypothalamic Amenorrhea?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1473-e1475.	1.8	1
10	Serum insulin-like factor 3 quantification by LCâ€“MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome. Endocrine, 2021, 71, 578-585.	1.1	3
11	Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Gravesâ€™ disease. Clinical Case Reports (discontinued), 2021, 9, 2281-2284.	0.2	6
12	Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3312-e3326.	1.8	10
13	Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushingâ€™s Disease: Final Results From the LINC 2 Study. Journal of the Endocrine Society, 2021, 5, A521-A522.	0.1	5
14	Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3505-3514.	1.8	4
15	Response to Letter to the Editor from Soghomonian: â€œEpicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndromeâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	0
16	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	5.5	34
17	Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 55-64.	1.8	7
18	Letter to the Editor: â€œLong-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomyâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e920-e921.	1.8	1

#	Article	IF	Citations
19	BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1449-e1457.	1.8	26
20	Testosterone replacement therapy in puberty. Current Opinion in Endocrine and Metabolic Research, 2020, 14, 73-77.	0.6	0
21	Pathogenic mosaic variants in congenital hypogonadotropic hypogonadism. Genetics in Medicine, 2020, 22, 1759-1767.	1.1	7
22	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Human Reproduction, 2020, 35, 2312-2322.	0.4	13
23	Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. Human Reproduction, 2020, 35, 939-949.	0.4	13
24	Non-invasive Diagnostic Strategy in ACTH-dependent Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3273-3284.	1.8	62
25	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. European Journal of Endocrinology, 2020, 182, 185.	1.9	21
26	MANAGEMENT OF ENDOCRINE DISEASE: Cushingâ€™s syndrome due to ectopic ACTH secretion: an expert operational opinion. European Journal of Endocrinology, 2020, 182, R29-R58.	1.9	120
27	SAT-010 Non-Classic POR Deficiency as a Cause of Menstrual Disorders & Infertility. Journal of the Endocrine Society, 2020, 4, .	0.1	0
28	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.2	1
29	Illicit Upregulation of Serotonin Signaling Pathway in Adrenals of Patients With High Plasma or Intra-Adrenal ACTH Levels. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4967-4980.	1.8	15
30	PCOS and Hyperprolactinemia: what do we know in 2019?. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811987192.	3.9	51
31	Prolactin Assays and Regulation of Secretion: Animal and Human Data. Contemporary Endocrinology, 2019, , 55-78.	0.3	3
32	Functional Characterization of Glucocorticoid Receptor Variants Is Required to Avoid Misinterpretation of NGS Data. Journal of the Endocrine Society, 2019, 3, 865-881.	0.1	5
33	Prolactin â€" a pleiotropic factor in health and disease. Nature Reviews Endocrinology, 2019, 15, 356-365.	4.3	148
34	Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocrine Reviews, 2019, 40, 669-710.	8.9	244
35	Selective modification of a native protein in a patient tissue homogenate using palladium nanoparticles. Chemical Communications, 2019, 55, 15121-15124.	2.2	4
36	ATG7 and ATG9A loss-of-function variants trigger autophagy impairment and ovarian failure. Genetics in Medicine, 2019, 21, 930-938.	1.1	55

#	Article	IF	Citations
37	Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused byGNRHRmutations and women with polycystic ovary syndrome. Human Reproduction, 2019, 34, 137-147.	0.4	10
38	Functional evidence implicating NOTCH2 missense mutations in primary ovarian insufficiency etiology. Human Mutation, 2019, 40, 25-30.	1.1	17
39	Hypogonadisme hypogonadotrophique congÃ©nital isolÃ© et syndrome de Kallmann chez la femme : diagnostic, exploration et traitement en 2019. , 2019, , 111-127.		0
40	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. Journal of the Endocrine Society, 2019, 3, .	0.1	0
41	Hepatic safety of ketoconazole in Cushingâ€™s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology, 2018, 178, 447-458.	1.9	46
42	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1772-1780.	3.3	62
43	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
44	GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. European Journal of Endocrinology, 2018, 178, R55-R80.	1.9	128
45	Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism. Endocrine, 2018, 59, 231-233.	1.1	4
46	Congenital Hypogonadotropic Hypogonadism in Females. , 2018, , 439-443.		0
47	Natural and molecular history of prolactinoma: insights from aPrlr-/â€“ mouse model. Oncotarget, 2018, 9, 6144-6155.	0.8	14
48	Foetal exposure to mitotane/Op'DDD: Postâ€natal study of four children. Clinical Endocrinology, 2018, 89, 805-812.	1.2	6
49	A novel mutation in <scp>KHDRBS</scp>1 in a patient affected by primary ovarian insufficiency. Clinical Endocrinology, 2018, 89, 245-246.	1.2	4
50	Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo. FASEB Journal, 2018, 32, 4791-4797.	0.2	19
51	New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Human Reproduction, 2017, 32, 1512-1520.	0.4	65
52	Anti-MÃ¼llerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1102-1111.	1.8	55
53	Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2844-2852.	1.8	28
54	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Research, 2017, 27, 649-652.	0.6	33

#	Article	IF	Citations
55	New MCM8 mutation associated with premature ovarian insufficiency and chromosomal instability in a highly consanguineous Tunisian family. Fertility and Sterility, 2017, 108, 694-702.	0.5	48
56	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. Journal of the Endocrine Society, 2017, 1, 221-230.	0.1	25
57	Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet Journal of Rare Diseases, 2017, 12, 57.	1.2	26
58	Society for Endocrinology <scp>UK</scp> guidance on the evaluation of suspected disorders of sexual development: emphasizing the opportunity to predict adolescent pubertal failure through a neonatal diagnosis of absent minipuberty. Clinical Endocrinology, 2017, 86, 305-306.	1.2	21
59	Effects of cortisol on the heart: characterization of myocardial involvement in cushing's disease by longitudinal cardiac MRI T1 mapping. Journal of Magnetic Resonance Imaging, 2017, 45, 147-156.	1.9	14
60	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society, 2017, 1, 1362-1371.	0.1	38
61	R-spondin2, a novel target of NOBOX: identification of variants in a cohort of women with primary ovarian insufficiency. Journal of Ovarian Research, 2017, 10, 51.	1.3	9
62	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. JCI Insight, 2017, 2, .	2.3	38
63	French law: what about a reasoned reimbursement of serum vitamin D assays?. Psychologie & Neuropsychiatrie Du Vieillissement, 2016, 14, 377-382.	0.2	7
64	AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocrine-Related Cancer, 2016, 23, 433-443.	1.6	24
65	Oneâ€year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes, Obesity and Metabolism, 2016, 18, 693-697.	2.2	46
66	<scp>IGSF</scp> 10 mutations dysregulate gonadotropinâ€releasing hormone neuronal migration resulting in delayed puberty. EMBO Molecular Medicine, 2016, 8, 626-642.	3.3	109
67	Testis ultrasound in Klinefelter syndrome infertile men: making the diagnosis and avoiding inappropriate management. Abdominal Radiology, 2016, 41, 1596-1603.	1.0	22
68	Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3450-3458.	1.8	118
69	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.4	47
70	Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. Neuroendocrinology, 2016, 103, 738-745.	1.2	17
71	Reversal of congenital hypogonadotropic hypogonadism in a man with Kallmann syndrome due to <scp>SOX</scp>10 mutation. Clinical Endocrinology, 2016, 85, 988-989.	1.2	19
72	Identification of Multiple Gene Mutations Accounts for a new Genetic Architecture of Primary Ovarian Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4541-4550.	1.8	99

#	Article	IF	Citations
73	Osilodrostat, a potent oral 11Î²-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushingâ€™s disease. Pituitary, 2016, 19, 138-148.	1.6	116
74	Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. European Journal of Endocrinology, 2016, 174, 523-530.	1.9	44
75	Flavor perception test: evaluation in patients with Kallmann syndrome. Endocrine, 2016, 52, 236-243.	1.1	16
76	PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease. JCI Insight, 2016, 1, e87958.	2.3	22
77	The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study. PLoS ONE, 2016, 11, e0152872.	1.1	12
78	Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. Orphanet Journal of Rare Diseases, 2015, 10, 71.	1.2	38
79	New insights in prolactin: pathological implications. Nature Reviews Endocrinology, 2015, 11, 265-275.	4.3	178
80	Sex Steroids, Precursors, and Metabolite Deficiencies in Men With Isolated Hypogonadotropic Hypogonadism and Panhypopituitarism: A GCMS-Based Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E292-E296.	1.8	38
81	New NOBOX Mutations Identified in a Large Cohort of Women With Primary Ovarian Insufficiency Decrease KIT-L Expression. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 994-1001.	1.8	48
82	Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies. Endocrine, 2015, 49, 865-866.	1.1	5
83	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2890-2898.	1.8	30
84	European Consensus Statement on congenital hypogonadotropic hypogonadismâ€”pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology, 2015, 11, 547-564.	4.3	664
85	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 2015, 22, 353-367.	1.6	151
86	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1177-1186.	1.8	83
87	Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology, 2015, 172, 473-481.	1.9	84
88	Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21-Hydroxylase Deficiency. A French National Survey. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2303-2313.	1.8	94
89	Ovarian macrocysts and gonadotropeâ€“ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. European Journal of Endocrinology, 2015, 172, 141-149.	1.9	19
90	Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4417-4424.	1.8	79

#	Article	IF	Citations
91	Secondary amenorrhoea associated with high serum 17â€hydroxyprogesterone levels revealing a heterozygous <scp>CYP</scp>21A2 mutation in a woman with Addison disease. Clinical Endocrinology, 2015, 82, 620-622.	1.2	2
92	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology, 2015, 173, 693-702.	1.9	44
93	The Lack of Antitumor Effects of o,pâ€²DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment. Hormones and Cancer, 2014, 5, 312-323.	4.9	19
94	Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2144-E2153.	1.8	65
95	131I-Noriodocholesterol Uptake by Testicular Adrenal Rest Tumors in a Patient With Classical 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3956-3957.	1.8	3
96	The Prevalence ofCHD7Missense Versus Truncating Mutations Is Higher in Patients With Kallmann Syndrome Than in Typical CHARGE Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2138-E2143.	1.8	81
97	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	2.3	155
98	Mitotane for 21-Hydroxylase Deficiency in an Infertile Man. New England Journal of Medicine, 2014, 371, 2042-2044.	13.9	28
99	Insulin-like Peptide 3 (INSL3) in Men With Congenital Hypogonadotropic Hypogonadism/Kallmann Syndrome and Effects of Different Modalities of Hormonal Treatment: A Single-Center Study of 281 Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E268-E275.	1.8	46
100	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	1.8	231
101	Testicular histological and immunohistochemical aspects in a post-pubertal patient with 5 alpha-reductase type 2 deficiency: case report and review of the literature in a perspective of evaluation of potential fertility of these patients. BMC Endocrine Disorders, 2014, 14, 43.	0.9	11
102	Ligand-dependent stabilization of androgen receptor in a novel mouse ST38c Sertoli cell line. Molecular and Cellular Endocrinology, 2014, 384, 32-42.	1.6	6
103	Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions. Annales D'Endocrinologie, 2014, 75, 79-87.	0.6	15
104	The testis through the ages. Annales D'Endocrinologie, 2014, 75, 31.	0.6	0
105	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4080-4088.	1.8	72
106	Intraadrenal Corticotropin in Bilateral Macronodular Adrenal Hyperplasia. New England Journal of Medicine, 2013, 369, 2115-2125.	13.9	176
107	Loss-of-Function Mutations in SOX10 Cause Kallmann Syndrome with Deafness. American Journal of Human Genetics, 2013, 92, 707-724.	2.6	177
108	Expression and characterization of androgen receptor coregulators, SRC-2 and HBO1, during human testis ontogenesis and in androgen signaling deficient patients. Molecular and Cellular Endocrinology, 2013, 375, 140-148.	1.6	12

#	Article	IF	Citations
109	Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in Individuals with Congenital Hypogonadotropic Hypogonadism. American Journal of Human Genetics, 2013, 92, 725-743.	2.6	227
110	Computed Tomography of the Anterior Skull Base in Kallmann Syndrome Reveals Specific Ethmoid Bone Abnormalities Associated With Olfactory Bulb Defects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E537-E546.	1.8	31
111	A man with a DAX1/NR0B1 mutation, normal puberty, and an intact hypothalamicâ€“pituitaryâ€“gonadal axis but deteriorating oligospermia during long-term follow-up. European Journal of Endocrinology, 2013, 168, K45-K50.	1.9	24
112	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	1.8	102
113	Kisspeptin Restores Pulsatile LH Secretion in Patients with Neurokinin B Signaling Deficiencies: Physiological, Pathophysiological and Therapeutic Implications. Neuroendocrinology, 2013, 97, 193-202.	1.2	137
114	Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-Related Cancer, 2013, 20, 371-381.	1.6	75
115	Two Families with Normosmic Congenital Hypogonadotropic Hypogonadism and Biallelic Mutations in KISS1R (KISS1 Receptor): Clinical Evaluation and Molecular Characterization of a Novel Mutation. PLoS ONE, 2013, 8, e53896.	1.1	38
116	R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism. PLoS ONE, 2013, 8, e69616.	1.1	16
117	No Evidence of a Detrimental Effect of Cabergoline Therapy on Cardiac Valves in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1714-E1719.	1.8	57
118	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	1.9	50
119	Germline AIP Mutations in Apparently Sporadic Pituitary Adenomas: Prevalence in a Prospective Single-Center Cohort of 443 Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E663-E670.	1.8	157
120	An ancient founder mutation in PROKR2 impairs human reproduction. Human Molecular Genetics, 2012, 21, 4314-4324.	1.4	31
121	Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. Journal of Clinical Investigation, 2012, 122, 3791-3795.	3.9	147
122	SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Human Reproduction, 2012, 27, 1460-1465.	0.4	133
123	Healthy birth after testicular extraction of sperm and <scp>ICSI</scp> from an azoospermic man with mild androgen insensitivity syndrome caused by an androgen receptor partial lossâ€ofâ€function mutation. Clinical Endocrinology, 2012, 77, 593-598.	1.2	22
124	Approach to the Male Patient with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 707-718.	1.8	100
125	Evidence for DNA-Binding Domainâ€“Ligand-Binding Domain Communications in the Androgen Receptor. Molecular and Cellular Biology, 2012, 32, 3033-3043.	1.1	52
126	Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nature Reviews Endocrinology, 2012, 8, 172-182.	4.3	124

#	Article	IF	Citations
127	Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment. Annales D'Endocrinologie, 2012, 73, 141-146.	0.6	38
128	SEMA3A, a Gene Involved in Axonal Pathfinding, Is Mutated in Patients with Kallmann Syndrome. PLoS Genetics, 2012, 8, e1002896.	1.5	190
129	Pharmacology of Hormone Replacement Therapy in Menopause. , 2012, , .		1
130	Congenital Hypogonadotropic Hypogonadism Due to GNRH Receptor Mutations in Three Brothers Reveal Sites Affecting Conformation and Coupling. PLoS ONE, 2012, 7, e38456.	1.1	35
131	Hypogonadisme hypogonadotrophique congÃ©nital chez la femme. , 2012, , 107-117.		0
132	Abstract 5754: Temozolomide therapy for progressive metastatic paraganglioma/pheochromocytoma: SDHB mutation as a prognosis biomarker for efficacy. , 2012, , .		0
133	REMOVAL: Pelvic MRI in a 17-year-old XY girl with 5-alpha reductase deficiency and a homozygous Gly115Asp mutation in SRD5A2. Annales D'Endocrinologie, 2011, 72, 310-313.	0.6	2
134	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2796-2804.	1.8	187
135	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects ofÂdifferent modalities of hormonal treatment. Fertility and Sterility, 2011, 95, 2324-2329.e3.	0.5	30
136	Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?. Hormones and Cancer, 2011, 2, 363-371.	4.9	36
137	Ectopic ACTH Syndrome in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1213-1222.	1.8	63
138	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2741-2749.	1.8	54
139	Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations. PLoS ONE, 2011, 6, e25614.	1.1	83
140	Genetics defects in GNRH1: A paradigm of hypothalamic congenital gonadotropin deficiency. Brain Research, 2010, 1364, 3-9.	1.1	24
141	Familial Glucocorticoid Receptor Haploinsufficiency by Non-Sense Mediated mRNA Decay, Adrenal Hyperplasia and Apparent Mineralocorticoid Excess. PLoS ONE, 2010, 5, e13563.	1.1	48
142	Kallmann Syndrome Caused by Mutations in the <i>PROK2</i> and <i>PROKR2</i> Genes: Pathophysiology and Genotype-Phenotype Correlations. Frontiers of Hormone Research, 2010, 39, 121-132.	1.0	42
143	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	1.6	52
144	A new FSHÎ² mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. European Journal of Endocrinology, 2010, 162, 633-641.	1.9	50

#	Article	IF	Citations
145	Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotypeâ€“phenotype relationships. European Journal of Endocrinology, 2010, 162, 835-851.	1.9	104
146	Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?. European Journal of Endocrinology, 2010, 162, 1147-1153.	1.9	126
147	Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology, 2010, 163, 193-200.	1.9	167
148	TAC3andTACR3Defects Cause Hypothalamic Congenital Hypogonadotropic Hypogonadism in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2287-2295.	1.8	214
149	A Comparative Phenotypic Study of Kallmann Syndrome Patients Carrying Monoallelic and Biallelic Mutations in the Prokineticin 2 or Prokineticin Receptor 2 Genes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 659-669.	1.8	124
150	Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics. Annales D'Endocrinologie, 2010, 71, 158-162.	0.6	34
151	Ovarian dysfunction by activating mutation of GS alpha: McCune-Albright syndrome as a model. Annales D'Endocrinologie, 2010, 71, 210-213.	0.6	12
152	Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. Annales D'Endocrinologie, 2010, 71, 14-18.	0.6	25
153	Female Gonadal Function before and after Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4518-4525.	1.8	77
154	Hypogonadotropic Hypogonadism and <i>GNRH1</i> Mutations in Mice and Humans. Frontiers of Hormone Research, 2010, 39, 111-120.	1.0	4
155	Isolated Familial Hypogonadotropic Hypogonadism and aGNRH1Mutation. New England Journal of Medicine, 2009, 360, 2742-2748.	13.9	247
156	Lack of Androgen Receptor Expression in Sertoli Cells Accounts for the Absence of Anti-Mullerian Hormone Repression during Early Human Testis Development. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1818-1825.	1.8	146
157	The Paradoxical Increase in Cortisol Secretion Induced by Dexamethasone in Primary Pigmented Nodular Adrenocortical Disease Involves a Glucocorticoid Receptor-Mediated Effect of Dexamethasone on Protein Kinase A Catalytic Subunits. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2406-2413.	1.8	75
158	Effects of Testosterone on Ventricular Repolarization in Hypogonadic Men. American Journal of Cardiology, 2009, 103, 887-890.	0.7	90
159	Acromegaly. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 555-574.	2.2	133
160	Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World Journal of Gastroenterology, 2009, 15, 328.	1.4	21
161	Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. Fertility and Sterility, 2008, 90, 1198.e1-1198.e5.	0.5	14
162	Kallmannâ€™s Syndrome: A Comparison of the Reproductive Phenotypes in Men Carrying KAL1 and FGFR1/KAL2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 758-763.	1.8	109

#	Article	IF	Citations
163	Human fetal testis: source of estrogen and target of estrogen action. Human Reproduction, 2007, 22, 1885-1892.	0.4	54
164	Prolactinoma andÂestrogens: pregnancy, contraception andÂhormonal replacement therapy. Annales D'Endocrinologie, 2007, 68, 106-112.	0.6	43
165	NovelFGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Human Mutation, 2007, 28, 97-98.	1.1	81
166	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	1.2	19
167	Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology, 2006, 64, 110-113.	1.2	48
168	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology, 2006, 65, 536-543.	1.2	142
169	Interferon-Î±-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Gravesâ€™ disease. European Journal of Endocrinology, 2006, 154, 367-372.	1.9	35
170	Kallmann Syndrome: Mutations in the Genes Encoding Prokineticin-2 and Prokineticin Receptor-2. PLoS Genetics, 2006, 2, e175.	1.5	391
171	McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin Analog-Resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4957-4961.	1.8	54
172	Kallmann syndrome: 14 novel mutations inKAL1andFGFR1(KAL2). Human Mutation, 2005, 25, 98-99.	1.1	141
173	Testicular Anti-MÃ¼llerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 724-728.	1.8	122
174	Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-1Â (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of the Young Type 5. Diabetes, 2005, 54, 3126-3132.	0.3	236
175	Type A Insulin Resistance Syndrome Revealing a Novel Lamin A Mutation. Diabetes, 2005, 54, 1873-1878.	0.3	75
176	Expression, Hormonal Regulation, and Subcellular Localization of CCAAT/Enhancer-Binding Protein-Î² in Rat and Human Thyrocytes. Thyroid, 2005, 15, 197-204.	2.4	8
177	Comparison of fast Fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients. International Journal of Cardiology, 2005, 104, 307-313.	0.8	60
178	Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5308-5313.	1.8	89
179	Pituitary Magnetic Resonance Imaging Findings Do Not Influence Surgical Outcome in Adrenocorticotropin-Secreting Microadenomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3371-3376.	1.8	94
180	Paradoxical Inhibitory Effect of Serotonin on Cortisol Production from Adrenocortical Lesions Causing Cushing's Syndrome. Endocrine Research, 2004, 30, 951-954.	0.6	12

#	Article	IF	Citations
181	Hypogonadismes hypogonadotrophiques chez l'homme. EMC - Endocrinologie - Nutrition, 2004, 1, 1-12.	0.0	1
182	Chromogranin A as serum marker of pituitary adenomas. Clinical Endocrinology, 2003, 59, 644-648.	1.2	11
183	Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nature Genetics, 2003, 33, 463-465.	9.4	764
184	Hypogonadotropic hypogonadism as a model of post-natal testicular anti-MÃ¼llerian hormone secretion in humans. Molecular and Cellular Endocrinology, 2003, 211, 51-54.	1.6	25
185	Overexpression of Serotonin4 Receptors in Cisapride-Responsive Adrenocorticotropin-Independent Bilateral Macronodular Adrenal Hyperplasia Causing Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 248-254.	1.8	75
186	Autoantibodies interacting with purified native thyrotropin receptor. FEBS Journal, 2001, 265, 1022-1031.	0.2	30
187	Prenatal testosterone treatment potentiates the aggression-inhibiting effect of the neurosteroid dehydroepiandrosterone in female mice. Aggressive Behavior, 2001, 27, 130-138.	1.5	13
188	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	1.8	101
189	The Postmenopausal Ovary Is Not a Major Androgen-Producing Gland. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5060-5066.	1.8	193
190	Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology, 2000, 53, 445-451.	1.2	70
191	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	1.8	72
192	Measurement of Plasma Free Luteinizing Hormone Â-Subunit in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2293-2298.	1.8	2
193	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	1.8	57
194	The Same Molecular Defects of the Gonadotropin-Releasing Hormone Receptor Determine a Variable Degree of Hypogonadism in Affected Kindred¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 567-572.	1.8	145
195	AntimÃ¼llerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	1.8	77
196	Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. European Journal of Endocrinology, 1999, 140, 187-191.	1.9	39
197	Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clinical Endocrinology, 1999, 50, 229-235.	1.2	92
198	The Same Molecular Defects of the Gonadotropin-Releasing Hormone Receptor Determine a Variable Degree of Hypogonadism in Affected Kindred. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 567-572.	1.8	118

#	Article	IF	Citations
199	Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	1.8	64
200	Le cycle ovarien : Endocrinologie de la reproduction. Medecine/Sciences, 1999, 15, 183.	0.0	2
201	Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. European Journal of Endocrinology, 1998, 139, 157-160.	1.9	25
202	Pitfall of Petrosal Sinus Sampling in a Cushing's Syndrome Secondary to Ectopic Adrenocorticotropin-Corticotropin Releasing Hormone (ACTH-CRH) Secretion. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 305-308.	1.8	48
203	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	1.8	116
204	Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1397-1402.	1.8	25
205	A Family with Hypogonadotropic Hypogonadism and Mutations in the Gonadotropin-Releasing Hormone Receptor. New England Journal of Medicine, 1997, 337, 1597-1603.	13.9	473
206	Neurosteroids: Deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in the hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14865-14870.	3.3	284
207	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	1.8	86
208	Neurosteroids in the mouse brain: Behavioral and pharmacological effects of a 3Î²-hydroxysteroid dehydrogenase inhibitor. Steroids, 1996, 61, 144-149.	0.8	49
209	A mouse mutant strain highly resistant to methyl ?-carboline-3-carboxylate-induced seizures. Experimental Brain Research, 1996, 110, 28-35.	0.7	6
210	The antigonadotropic activity of progestins (19-nortestosterone and 19- norprogesterone derivatives) is not mediated through the androgen receptor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4218-4223.	1.8	19
211	Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2994-2998.	1.8	63
212	Aromatase expression in a feminizing adrenocortical tumor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3173-3176.	1.8	52
213	Biosynthesis and assay of neurosteroids in rats and mice: Functional correlates. Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 355-360.	1.2	104
214	Even after priming with ovarian steroids or pulsatile gonadotropin- releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2102-2107.	1.8	14
215	Primary adrenal and thyroid insufficiencies associated with hypopituitarism: a diagnostic challenge. Clinical Endocrinology, 1994, 40, 693-695.	1.2	20
216	Plasma 3 beta-hydroxy-delta 5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 299-304.	1.8	12

#	Article	IF	Citations
217	The impact of a pure antiâ€androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clinical Endocrinology, 1993, 39, 157-162.	1.2	65
218	Xp22.3 deletions in isolated familial Kallmann's syndrome. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 827-831.	1.8	63
219	Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism [published erratum appears in J Clin Endocrinol Metab 1994 Apr;78(4):846]. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1545-1549.	1.8	66
220	Neurosteroids: pregnenolone in human sciatic nerves.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6790-6793.	3.3	64
221	Suppressive effects of dehydroepiandrosterone and 3Î²-methyl-androst-5-en-17-one on attack towards lactating female intruders by castrated male mice. II. Brain neurosteroids. Biochemical and Biophysical Research Communications, 1991, 174, 892-897.	1.0	69
222	Neurosteroids: Biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 71-81.	1.2	158
223	Pregnenolone, dehydroepiandrosterone, and their sulfate and fatty acid esters in the rat brain. Steroids, 1989, 54, 287-297.	0.8	115
224	The use of e-REC for capturing the occurrence of covid-19 infections in people with rare endocrine conditions. Endocrine Abstracts, 0, , .	0.0	0
225	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. , 0, .		19
226	Exome sequencing as a tool for detecting point mutations and deletions in patients with hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0